Clinical Trial Data
English
Canada, Toronto
Science Products Stories
数据描述
We publicly share results from our clinical trials, whether the results are neutral, negative, or positive. We also share data gathered in clinical trials we sponsor with trial volunteers, researchers, and others.
www.pfizer.com
IP: 104.18.35.94
加载中...
相关论文
36Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
Scott Kopetz•Danielle A. Murphy•Jie Pu•Fortunato Ciardiello•Jayesh Desai等 14 人
Nature Medicine
2024
•2024/9/23
•00 p.1-11
The BEACON CRC study demonstrated that encorafenib (Enco)+cetuximab (Cetux)±binimetinib (Bini) significantly improved overall survival (OS) versus Cetux + chemotherapy in previously treated patients with BRAF-V600E-mutant mCRC, providing the basis for the approval of the Enco+Cetux regimen in the Un...
BiomarkersCancerGeneticsMedical researchMolecular biology
10.1038/S41591-024-03235-9
ISSN:1078-8956
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Alexander Drilon•Jeffrey W. Clark•Jared Weiss•Sai-Hong Ignatius Ou•D. Ross Camidge等 21 人
Nature Medicine
2020
•2020/1/13
•Vol.26 No.1 p.47-51
MET exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs)1. These alterations are associated with increased MET activity and preclinical sensitivity to MET inhibition2. Crizotinib is a multikinase inhibitor with potent activity against MET3. The antitumor activity and saf...
Non-small-cell lung cancerTumour biomarkers
10.1038/S41591-019-0716-8
ISSN:1078-8956
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
Daniel J. DeAngelo•Anjali S. Advani•David I. Marks•Matthias Stelljes•Michaela Liedtke等 14 人
Blood Cancer Journal
2020
•2020/8/7
•Vol.10 No.8 p.1-11
Adults with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) have a poor prognosis, especially if disease burden is high. This post hoc analysis of the phase 3 INO-VATE trial examined the efficacy and safety of inotuzumab ozogamicin (InO) vs. standard of care chemotherapy (SC) among R/R AL...
Acute lymphocytic leukaemiaTargeted therapies
10.1038/S41408-020-00345-8
ISSN:2044-5385
AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial
Russell J. Butterfield•Perry B. Shieh•Huihua Li•Michael Binks•Tara G. McDonnell等 12 人
Nature Medicine
2025
•2025/6/27
•00 p.1-10
Gene therapy represents a promising approach for Duchenne muscular dystrophy (DMD), a rare X-linked genetic muscle disease. Fordadistrogene movaparvovec (PF-06939926) is an adeno-associated virus serotype 9 gene therapy containing a miniaturized dystrophin being developed for DMD, which aims to rest...
Diseases of the nervous systemMolecular neuroscienceNeuroscience
10.1038/S41591-025-03750-3
ISSN:1078-8956
Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy
Farrokhi Vahid•Walsh Jason•Palandra Joe•Brodfuehrer Joanne•Caiazzo Teresa等 12 人
Gene Therapy
2021
•2021/11/5
•00 p.1-8
Duchenne muscular dystrophy (DMD) is a lethal, degenerative muscle disorder caused by mutations in the DMD gene, leading to severe reduction or absence of the protein dystrophin. Gene therapy strategies that aim to increase expression of a functional dystrophin protein (mini-dystrophin) are under in...
Gene expressionGene expression analysisNeurological disorders
10.1038/S41434-021-00300-7
ISSN:0969-7128
Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine
Shannon L. Harris•Cuiwen Tan•John Perez•David Radley•Kathrin U. Jansen等 7 人
Npj Vaccines
2020
•2020/1/29
•Vol.5 No.1 p.1-9
MenB-FHbp is a recombinant meningococcal serogroup B (MenB) vaccine composed of 2 factor H binding proteins (FHbps). Meningococcal vaccines targeting polysaccharide serogroup A, C, Y, and W capsules were licensed upon confirmation of bactericidal antibody induction after initial efficacy studies wit...
MeningitisVaccines
10.1038/S41541-019-0154-0
ISSN:2059-0105
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial
Aditi R. Saxena•Donal N. Gorman•Ryan M. Esquejo•Arthur Bergman•Kristin Chidsey等 8 人
Nature Medicine
2021
•2021/6/14
•00 p.1-9
Agonism of the glucagon-like peptide-1 receptor (GLP-1R) results in glycemic lowering and body weight loss and is a therapeutic strategy to treat type 2 diabetes (T2D) and obesity. We developed danuglipron (PF-06882961), an oral small-molecule GLP-1R agonist and found it had comparable efficacy to i...
Drug developmentTranslational research
10.1038/S41591-021-01391-W
ISSN:1078-8956
Longitudinal voice monitoring in a decentralized Bring Your Own Device trial for respiratory illness detection
Mar Santamaria•Yiorgos Christakis•Charmaine Demanuele•Yao Zhang•Pirinka Georgiev Tuttle等 21 人
Npj Digital Medicine
2025
•2025/4/11
•Vol.8 No.1 p.1-12
The Acute Respiratory Illness Surveillance (AcRIS) Study was a low-interventional trial that examined voice changes with respiratory illnesses. This longitudinal trial was the first of its kind, conducted in a fully decentralized manner via a Bring Your Own Device mobile application. The app enabled...
Machine learningRespiratory tract diseasesStatistical methodsClinical trial design
10.1038/S41746-025-01584-4
ISSN:2398-6352
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK
Ugo De Giorgi•Stephen J. Freedland•Antti Rannikko•Miguel Ramirez-Backhaus•Arnauld Villers等 10 人
Prostate Cancer And Prostatic Diseases
2025
•2025/3/26
•00 p.1-4
High-risk biochemical recurrence (BCR) definition varies across clinical studies/practice guidelines. We evaluated metastasis-free survival (MFS) by blinded, independent, central review and safety in EMBARK (NCT02319837) patients defined as high-risk BCR per European Association of Urology (EAU) cri...
Prostate cancer
10.1038/S41391-025-00959-8
ISSN:1365-7852
A Phase 1/2 study of ontorpacept (TTI-621) in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma
Sujana Movva•Victoria Allgood•Rashmi Chugh•Lara E. Davis•Howard H. Bailey等 18 人
British Journal Of Cancer
2026
•2026/8/4
•00 p.1-13
Ontorpacept, a recombinant signal regulatory protein alpha (SIRPα)–blocking fusion protein, has antitumour activity by disrupting CD47–SIRPα signalling. This Phase 1/2 study examined ontorpacept with doxorubicin in patients with leiomyosarcoma. Eligible patients were ≥18 years with metastatic or loc...
Molecular medicineOncology
10.1038/S41416-026-03574-Z
ISSN:0007-0920
Development of digital measures for nighttime scratch and sleep using wrist-worn wearable devices
Nikhil Mahadevan•Yiorgos Christakis•Junrui Di•Jonathan Bruno•Yao Zhang等 16 人
Npj Digital Medicine
2021
•2021/3/3
•Vol.4 No.1 p.1-10
Patients with atopic dermatitis experience increased nocturnal pruritus which leads to scratching and sleep disturbances that significantly contribute to poor quality of life. Objective measurements of nighttime scratching and sleep quantity can help assess the efficacy of an intervention. Wearable ...
Atopic dermatitisDrug developmentQuality of lifeSkin manifestations
10.1038/S41746-021-00402-X
ISSN:2398-6352
Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2− MBC patients living in disadvantaged neighborhoods
Filipa Lynce•Xianchen Liu•Benjamin Li•Lynn McRoy•Connie Chen等 7 人
Npj Breast Cancer
2025
•2025/7/21
•Vol.11 No.1 p.1-11
Palbociclib (PAL) combined with endocrine therapy (ET) is approved for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2− ) advanced/metastatic breast cancer (MBC). However, there is limited data on the effectiveness of PAL + ET in patients with MBC and low socioe...
Breast cancerHealth care economics
10.1038/S41523-025-00786-Z
ISSN:2374-4677
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Scott Kopetz•Takayuki Yoshino•Eric Van Cutsem•Cathy Eng•Tae Won Kim等 15 人
Nature Medicine
2025
•2025/1/25
•Vol.31 No.3 p.901-908
Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study. Historically, first-line treatment of BRAF V600E-mutant mCRC with chemotherapy regimens has had limited efficacy. The phase 3 BREAKWATER study inve...
Colorectal cancerGastrointestinal cancer
10.1038/S41591-024-03443-3
ISSN:1078-8956
Monitoring Activity and Gait in Children (MAGIC) using digital health technologies
Junrui Di•Pirinka Georgiev Tuttle•Lukas Adamowicz•Wenyi Lin•Hao Zhang等 16 人
Pediatric Research
2024
•2024/3/21
•00 p.1-9
Digital health technologies (DHTs) can collect gait and physical activity in adults, but limited studies have validated these in children. This study compared gait and physical activity metrics collected using DHTs to those collected by reference comparators during in-clinic sessions, to collect a n...
Medicine/Public Health, generalPediatricsPediatric Surgery
10.1038/S41390-024-03147-X
ISSN:0031-3998
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
Calle Roberto A.•Amin Neeta B.•Carvajal-Gonzalez Santos•Ross Trenton T.•Bergman Arthur等 21 人
Nature Medicine
2021
•2021/10/11
•Vol.27 No.10 p.1836-1848
Alterations in lipid metabolism might contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, no pharmacological agents are currently approved in the United States or the European Union for the treatment of NAFLD. Two parallel phase 2a studies investigated the effects o...
Drug discoveryLipidsNon-alcoholic fatty liver diseaseNon-alcoholic steatohepatitis
10.1038/S41591-021-01489-1
ISSN:1078-8956
Global disparities in patients with multiple myeloma: a rapid evidence assessment
Maria-Victoria Mateos•Sikander Ailawadhi•Luciano J. Costa•Shakira J. Grant•Lalit Kumar等 8 人
Blood Cancer Journal
2023
•2023/7/18
•Vol.13 No.1 p.1-9
There are disparities in outcomes for patients with multiple myeloma (MM). We evaluated the influence of sociodemographic factors on global disparities in outcomes for patients with MM. This rapid evidence assessment (PROSPERO, CRD42021248461) followed PRISMA-P guidelines and used the PICOS framewor...
MyelomaQuality of life
10.1038/S41408-023-00877-9
ISSN:2044-5385
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial
Mikkael A. Sekeres•Pau Montesinos•Jan Novak•Jianxiang Wang•Deepa Jeyakumar等 20 人
Leukemia
2023
•2023/8/21
•00 p.1-10
This is the primary report of the randomized, placebo-controlled phase 3 BRIGHT AML 1019 clinical trial of glasdegib in combination with intensive chemotherapy (cytarabine and daunorubicin) or non-intensive chemotherapy (azacitidine) in patients with untreated acute myeloid leukemia. Overall surviva...
Targeted therapies
10.1038/S41375-023-02001-Z
ISSN:0887-6924
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial
Brümmendorf Tim H.•Cortes Jorge E.•Milojkovic Dragana•Gambacorti-Passerini Carlo•Clark Richard E.等 19 人
Leukemia
2022
•2022/5/28
•00 p.1-9
This analysis from the multicenter, open-label, phase 3 BFORE trial reports efficacy and safety of bosutinib in patients with newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) after five years’ follow-up. Patients were randomized to 400-mg once-daily bosutinib (n = 268) or imatinib (...
Haematological cancerRandomized controlled trials
10.1038/S41375-022-01589-Y
ISSN:0887-6924
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
Robert J. Motzer•Paul B. Robbins•Thomas Powles•Laurence Albiges•John B. Haanen等 23 人
Nature Medicine
2020
•2020/9/7
•Vol.26 No.11 p.1733-1741
We report on molecular analyses of baseline tumor samples from the phase 3 JAVELIN Renal 101 trial (n = 886; NCT02684006 ), which demonstrated significantly prolonged progression-free survival (PFS) with first-line avelumab + axitinib versus sunitinib in advanced renal cell carcinoma (aRCC). We foun...
BiomarkersRenal cell carcinoma
10.1038/S41591-020-1044-8
ISSN:1078-8956
A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults
Haranaka Miwa•Baber James•Ogama Yoichiro•Yamaji Masako•Aizawa Masakazu等 13 人
Nature Communications
2021
•2021/12/14
•Vol.12 No.1 p.1-7
We report interim safety and immunogenicity findings from an ongoing phase 1/2 study of BNT162b2 in healthy Japanese adults. Participants were randomized 3:1 to receive 2 intramuscular injections of 30 μg BNT162b2 or placebo 21 days apart. Overall, 160 individuals were randomized: 119 received BNT16...
Phase I trialsRNA vaccinesSARS-CoV-2
10.1038/S41467-021-27316-2
ISSN:2041-1723
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Alexander M. Lesokhin•Michael H. Tomasson•Bertrand Arnulf•Nizar J. Bahlis•H. Miles Prince等 29 人
Nature Medicine
2023
•2023/8/15
•00 p.1-9
Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after two step-up priming doses. After six cycles, persistent responders...
Cancer immunotherapyDrug developmentMyeloma
10.1038/S41591-023-02528-9
ISSN:1078-8956
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial
Powles Thomas•Sridhar Srikala S.•Loriot Yohann•Bellmunt Joaquim•Mu Xinmeng Jasmine等 16 人
Nature Medicine
2021
•2021/12/10
•Vol.27 No.12 p.2200-2211
In a recent phase 3 randomized trial of 700 patients with advanced urothelial cancer (JAVELIN Bladder 100; NCT02603432 ), avelumab/best supportive care (BSC) significantly prolonged overall survival relative to BSC alone as maintenance therapy after first-line chemotherapy. Exploratory biomarker ana...
Bladder cancerImmunotherapyPredictive markersSequencingTranscriptomics
10.1038/S41591-021-01579-0
ISSN:1078-8956
Dystrophin/mini-dystrophin expression analysis by immunoaffinity liquid chromatography–tandem mass spectrometry after gene therapy for DMD
Jason Walsh•Joe Palandra•Nicole Duriga•David Beidler•Avery McIntosh等 7 人
Gene Therapy
2025
•2025/8/2
•00 p.1-8
Adeno-associated virus (AAV)-based gene replacement therapies in Duchenne muscular dystrophy (DMD) aim to restore dystrophin function via the introduction of micro- or mini-dystrophins. We report dystrophin and mini-dystrophin concentrations generated by immunoaffinity liquid chromatography–tandem m...
Biomedicine, generalHuman GeneticsCell BiologyNanotechnologyGene TherapyGene Expression
10.1038/S41434-025-00554-5
ISSN:0969-7128
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
Nizar J. Bahlis•Caitlin L. Costello•Noopur S. Raje•Moshe Y. Levy•Bhagirathbhai Dholaria等 19 人
Nature Medicine
2023
•2023/10/2
•00 p.1-7
Multiple myeloma (MM) is a plasma cell malignancy expressing B cell maturation antigen (BCMA). Elranatamab, a bispecific antibody, engages BCMA on MM and CD3 on T cells. The MagnetisMM-1 trial evaluated its safety, pharmacokinetics and efficacy. Primary endpoints, including the incidence of dose-lim...
Myeloma
10.1038/S41591-023-02589-W
ISSN:1078-8956
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up
Eva Domingo-Domènech•Barbara Pro•Tim Illidge•Steven Horwitz•Lorenz Trumper等 27 人
Blood Cancer Journal
2025
•2025/8/1
•Vol.15 No.1 p.1-5
Trial registration: ClinicalTrials.gov number: NCT01777152
Drug developmentMolecularly targeted therapyT-cell lymphoma
10.1038/S41408-025-01329-2
ISSN:2044-5385
Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial
Neal D. Shore•Thomas B. Powles•Jens Bedke•Matthew D. Galsky•Joan Palou Redorta等 21 人
Nature Medicine
2025
•2025/5/31
•00 p.1-9
Bacillus Calmette–Guérin (BCG) induction and maintenance (I+M) after transurethral resection of bladder tumor is standard of care (SOC) in high-risk non-muscle invasive bladder cancer (NMIBC). However, disease recurrence/progression occurs in approximately 40% of patients at 2 years, with unfavorabl...
Bladder cancer
10.1038/S41591-025-03738-Z
ISSN:1078-8956
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial
Alicia F. C. Okines•Giuseppe Curigliano•Nobumasa Mizuno•Do-Youn Oh•Andree Rorive等 31 人
Nature Medicine
2025
•2025/1/17
•00 p.1-8
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell growth and differentiation, and is overexpressed in several tumor types, including breast, gastric and colorectal cancer. HER2-targeted therapies have shown clinical activity against these tumor types, resul...
Breast cancer
10.1038/S41591-024-03462-0
ISSN:1078-8956
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Mark J. Mulligan•Kirsten E. Lyke•Nicholas Kitchin•Judith Absalon•Alejandra Gurtman等 25 人
Nature
2020
•2020/8/12
•Vol.586 No.7830 p.589-593
In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1, a pandemic. With rapidly accumulating numbers of cases and deaths reported globally2, a vaccine is urgently needed. Here ...
Drug developmentRandomized controlled trialsSARS-CoV-2Viral infection
10.1038/S41586-020-2639-4
ISSN:0028-0836
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study
Gianantonio Rosti•Tim H. Brümmendorf•Björn T. Gjertsen•Pilar Giraldo-Castellano•Fausto Castagnetti等 12 人
Leukemia
2023
•2023/11/25
•00 p.1-10
In the phase 4 BYOND trial, patients with pretreated chronic myeloid leukemia (CML) received bosutinib (starting dose: 500 mg/day). Efficacy and safety after ≥3 years of follow-up in 156 patients with Philadelphia chromosome–positive chronic phase CML by age and Charlson Comorbidity Index scores (wi...
Chronic myeloid leukaemiaPhase IV trials
10.1038/S41375-023-02080-Y
ISSN:0887-6924
Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial
Carlo Gambacorti-Passerini•Tim H. Brümmendorf•Elisabetta Abruzzese•Kevin R. Kelly•Vivian G. Oehler等 14 人
Leukemia
2024
•2024/8/20
•00 p.1-9
This final analysis from the phase 4 BYOND trial reports outcomes with bosutinib in patients with previously treated chronic myeloid leukemia (CML); 163 patients with CML resistant/intolerant to previous tyrosine kinase inhibitors received bosutinib (starting dose: 500 mg QD). At study completion (m...
Chronic myeloid leukaemiaPhase IV trials
10.1038/S41375-024-02372-X
ISSN:0887-6924
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies
Maggie Chon U. Cheang•Mothaffar Rimawi•Stephen Johnston•Samuel A. Jacobs•Judith Bliss等 19 人
Npj Breast Cancer
2024
•2024/6/29
•Vol.10 No.1 p.1-9
Intrinsic breast cancer molecular subtyping (IBCMS) provides significant prognostic information for patients with breast cancer and helps determine treatment. This study compared IBCMS methods on various gene-expression platforms in PALOMA-2 and PALLET trials. PALOMA-2 tumor samples were profiled us...
Breast cancerPredictive markers
10.1038/S41523-024-00658-Y
ISSN:2374-4677
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study
Nicholas C. Turner•A. Douglas Laird•Melinda L. Telli•Hope S. Rugo•Audrey Mailliez等 18 人
Npj Breast Cancer
2023
•2023/10/6
•Vol.9 No.1 p.1-9
These analyses explore the impact of homologous recombination repair gene mutations, including BRCA1/2 mutations and homologous recombination deficiency (HRD), on the efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib in the open-label, two-cohort, Phase 2 ABRAZO trial in germl...
Breast cancerPharmacogenomicsTumour biomarkers
10.1038/S41523-023-00561-Y
ISSN:2374-4677
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
Zhu Zhou•Turner Nicholas C.•Loi Sherene•André Fabrice•Martin Miguel等 21 人
Npj Precision Oncology
2022
•2022/8/16
•Vol.6 No.1 p.1-10
While cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, combined with endocrine therapy (ET), are becoming the standard-of-care for hormone receptor–positive/human epidermal growth factor receptor 2‒negative metastatic breast cancer, further mechanistic insights are needed to m...
Breast cancerPredictive markers
10.1038/S41698-022-00297-1
ISSN:2397-768X
Maternal 6-valent group B Streptococcus vaccine in non-pregnant and pregnant females: a randomized phase 1/2 trial
Shabir A. Madhi•Hasra Snaggs•Zahra Skogeby•Ye Feng•Shaun Barnabas等 18 人
Nature Medicine
2026
•2026/7/28
•00 p.1-12
Group B Streptococcus (GBS) disease is a major cause of infant morbidity and mortality. Capsular polysaccharide conjugate GBS vaccines have been evaluated for decades; however, none is licensed. This phase 1/2 trial evaluated an investigational maternal hexavalent polysaccharide−protein conjugate GB...
Bacterial infectionDiseasesPaediatricsVaccines
10.1038/S41591-026-04558-5
ISSN:1078-8956
Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial
Toru Mukohara•Yeon Hee Park•David Sommerhalder•Kan Yonemori•Erika Hamilton等 26 人
Nature Medicine
2024
•2024/6/1
•00 p.1-9
Inhibition of histone lysine acetyltransferases (KATs) KAT6A and KAT6B has shown antitumor activity in estrogen receptor-positive (ER+) breast cancer preclinical models. PF-07248144 is a selective catalytic inhibitor of KAT6A and KAT6B. In the present study, we report the safety, pharmacokinetics (P...
Drug developmentTarget validation
10.1038/S41591-024-03060-0
ISSN:1078-8956
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Karim Fizazi•Arun A. Azad•Nobuaki Matsubara•Joan Carles•Andre P. Fay等 21 人
Nature Medicine
2023
•2023/12/4
•00 p.1-8
Preclinical evidence has suggested an interplay between the androgen receptor, which largely drives the growth of prostate cancer cells, and poly(ADP-ribose) polymerase. This association provides a rationale for their co-inhibition for the treatment of metastatic castration-resistant prostate cancer...
Prostate cancer
10.1038/S41591-023-02704-X
ISSN:1078-8956